NRXP Stock Catalyst: NRx Pharmaceuticals and Hope Therapeutics Announce Acquisition of Kadima Neuropsychiatry Institute

Jan 2, 2025 · 4:00am ET

The acquisition aims to expand their international network of interventional psychiatry clinics.

Max move

+51.1%

High of day $3.40

Sparker timei

4:00am ET

NRXP · Jan 2, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and Hope Therapeutics have announced their plans to acquire Kadima Neuropsychiatry Institute. This strategic move is intended to enhance their global footprint in interventional psychiatry.

The acquisition will integrate Kadima's established network of clinics into the combined entity, aiming to bolster research and treatment capabilities in neuropsychiatry.

NRx Pharmaceuticals currently has a free float of 20,326,400 shares and 29,605,200 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time NRXP sparks.

Download Sniper App →

Catch the next NRXP-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →